Neurocrine (NBIX) CRO Ingrid Delaet Receives Award

What Happened

• Ingrid Delaet, Chief Regulatory Officer of Neurocrine Biosciences (NBIX), was issued 4,483 shares on September 11, 2026 as the result of vested performance restricted stock units (PRSUs) (award at $0.00 per share).
• To satisfy tax withholding on the vesting, the company withheld 2,419 shares valued at $156.22 each, equal to $377,896 (these were withheld for taxes — no shares were sold). Net delivered to the insider after withholding was 2,064 shares.
• This was an award/vesting event (not an open-market purchase or sale) tied to certified performance metrics.

Key Details

• Transaction date: 2026-09-11. Form 4 filed: 2026-09-15 (filed on time).
• Award: 4,483 shares @ $0.00 (code A — grant/award/acquisition upon vesting).
• Tax withholding: 2,419 shares withheld @ $156.22 (code F) — $377,896 withheld to cover taxes; filing notes “no shares were sold.”
• Net shares delivered: 2,064 (4,483 granted minus 2,419 withheld).
• Shares owned after transaction: Not reported on the Form 4 provided.
• Footnotes: F1 — PRSUs vested after certification of performance on 9/11/2026. F2 — withholding to satisfy tax obligation; not an open-market sale.

Context

• This was a compensation-related vesting of PRSUs tied to performance, not a market purchase or sale; withholding of shares for taxes is a common administrative step and should not be read as a liquidity-driven sale.
• The economic value of the full award at the reported price (~$156.22) was roughly $700,300, with about $377,900 withheld for taxes.